TSE:4559Pharmaceuticals
Zeria Pharmaceutical (TSE:4559) Margin Decline Tests Bullish Undervaluation Narrative
Zeria Pharmaceutical (TSE:4559) FY 2026 earnings snapshot
Zeria Pharmaceutical (TSE:4559) has wrapped up FY 2026 with fourth quarter revenue of ¥25,081.8 million and Basic EPS of ¥65.79. On a trailing 12 month basis, the company reported revenue of ¥89,159 million and Basic EPS of ¥191.79. Quarterly revenue increased from ¥22,538 million in Q4 FY 2025 to ¥25,081.8 million in Q4 FY 2026, while Basic EPS rose from ¥38.79 to ¥65.79 over the same period, providing a clearer view of how the top...